

CHICS NEWS

Celebrating Hope in Cancer Survivors



Through the years we have grown by the number of attendees at our monthly meetings. We continue to produce and distribute a quarterly newsletter, participate and plan local events, and established a Phone Bank, which is used

as a support resource for newly diagnosed breast cancer patients. We also provide and fill tote bags with information for newly diagnosed women that are distributed through the breast center.

UP COMING EVENTS

September 38th-30th


2018 Living Beyond Breast Cancer Conference



Whether you are recently diagnosed with breast cancer, are in treatment or years beyond it, you have questions. The 2018 Living Beyond Breast Cancer Conference addresses them. Leading medical professionals, people affected by breast cancer, and caregivers share their experiences, knowledge and concerns with one another.

UP COMING MEETINGS

July 10th



Ice Cream Social- Bring your favorite topping for a night of ice cream & sharing!

August 14th



TBD

September 11th



Kathryn Peroutka, MD advances in Chemotherapy.

"The Pessimist Sees Difficulty In Every Opportunity. The Optimist Sees Opportunity In Every Difficulty." - Winston Churchill

News & Education MyLifeLine

Cancer Support Community is a great resource for individuals who have been diagnosed with cancer or those who are cancer survivors. The charitable organization offers emotional and social support as well as educational resources for patients and survivors. They also deliver a comprehensive menu of personalized and essential services including support groups, counseling, education and healthy lifestyle programs. It offers a network of community-

based centers and online services run by trained and licensed professionals. As of January of 2018, Cancer Support Community recently announced their partnership with MyLifeLine, which is a personalized digital platform that patients and survivors can share updates and manage caring messages via one central website to help everyone touched by cancer deal with it. Learn More - www.mylifeline.org

News & Education Cont. TAILORx Study

New results from the TAILORx study published just earlier this month at the 2018 ASCO Annual Meeting announced that about 70% of women diagnosed with hormone-receptor-positive, HER2-negative breast cancer that has not spread to the lymph nodes do not need chemotherapy after surgery.

The TAILORx study has been following 10,273 women diagnosed with hormone-receptor-positive, HER2-negative breast cancer that had not spread to the lymph nodes.

Researchers performed Oncotype DX tests on tissues samples from all the cancers, and all the women were then assigned an Oncotype DX recurrence score from a range of 0-100 for early stage breast cancer. The following is a breakdown of the range of scores for the Oncotype DX for early

stage invasive breast cancer:

- Recurrence Score lower than 18: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects.
- Recurrence Score of 18 up to and including 30: The cancer has an intermediate risk of recurrence. It's unclear whether the benefits of chemotherapy outweigh the risks of side effects.
- Recurrence Score greater than or equal to 31: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects.

All in the all, the results of the TAILORx study were promising. These results suggest that three groups of women diagnosed with hormone-receptor-positive,

HER2-negative, node-negative breast cancer can safely skip chemotherapy, and are as follows:

- Women with a Recurrence Score between 0 and 10
- Women older than 50 with a Recurrence Score between 11 and 25
- Women 50 and younger with a Recurrence Score between 11 and 15

(Breastcancer.org, 2018)

Check out this link for the full article:

<http://www.breastcancer.org/research-news/oncotypedx-intermediate-results-skip-chemo>



Notes:

